Jubilant Biosys Limited (JB) stands at the forefront of the pharmaceutical and health science sectors, offering a comprehensive suite of services encompassing drug discovery, contract research, development, and manufacturing. Its client base includes Pharmaceuticals, Biotech, and AI/ML companies.

In recent years, JB has achieved remarkable growth, and its vision extends to ambitious plans for future expansion. The dedicated team comprises over 1,120 highly talented scientists, with operations in India and a presence in Europe, the USA, and Japan, all motivated by a science and solution-oriented mindset. This unwavering commitment to innovation lies at the core of the company's mission: to conceive and bring new medicines to life swiftly

JB's primary objective is to expedite the identification and industrialization of the most promising molecules for its valued customers, all while meticulously adhering to industrial and compliance standards. The company brings a unique expertise to the table, offering fully integrated drug discovery programs (NCEs), along with extensive experience in Process Research Development and Manufacturing of advanced and complex intermediates and Active Pharmaceutical Ingredients (APIs). JB's unwavering commitment to integrity and excellence is upheld through world-class Quality Management Systems (FDA, EUA, PMDA certified), Project Management, Environmental, Health, and Safety (EHS) protocols, and cutting-edge digital and cybersecurity infrastructure.

To enhance the trust of its clients, JB has focused on three pivotal priorities:

- Attracting and retaining the best talent.

- Establishing state-of-the-art infrastructure.

- Developing cutting-edge capabilities and fostering consistent innovation.

These endeavours are meticulously integrated into a well-defined roadmap. In the relentless pursuit of progress and innovation, the company is committed to investing in new capabilities, advanced platforms, and digital technology.

In 2021, JB inaugurated six Centres of Excellence at its New Delhi Research Centre, which is home to more than 600 scientists. These centres are focal points for innovation in advanced fields such as LIPID Chemistry, Carbohydrate Chemistry, and Electro and Photochemistry. This strategic initiative, coupled with the company's expanded capacity, offers its clients access to a comprehensive range of complex chemistry services, from milligrams to kilograms, all conveniently available in one location. This streamlined approach accelerates the development and scale-up of their programs, underpinning JB's dedication to promoting innovation and delivering exceptional value to its clients and stakeholders.

To further expedite the Discovery programs, JB is actively engaged in specific projects, including its hybrid AI/ML Drug Discovery Platform. This platform is aptly named 'hybrid' because it unites a unique team of experts from both the IT and scientific domains, fostering a decade-long collaboration. This close-knit partnership within a single team enables the company to swiftly identify new medicines and drive innovation for its clients.

‍

About Jubilant Biosys

Jubilant Biosys Limited is a subsidiary of Jubilant Pharmova Limited, listed on the Indian Stock Exchanges and one of the flagship companies of the Jubilant Bhartia Group. The Group was founded by the visionary leaders Shyam S Bhartia and Hari S Bhartia. With a global workforce of around 43,000 employees, the Group has a strong presence in diverse sectors, including Pharmaceuticals, Life Science Ingredients, Contract Research & Development Services, Therapeutics, Performance Polymers, Food Service (QSR), Food, Auto, Aerospace Consulting, and Oilfield Services.